Suchergebnisse - "Hellmann, Mark A"

PubPharm (4)

1

Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis

enthalten in: Neuromuscular disorders : NMD | 2022

von Lotan, I. | Hellmann, M. | Friedman, Y. | +3

2

Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis : An Israeli Multi-Center Experience Following 3 Vaccine Doses

enthalten in: Frontiers in immunology | 2022

von Milo, R. | Staun-Ram, E. | Karussis, D. | +33

3

Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS) : Early experience from a tertiary MS center in Israel

enthalten in: European journal of neurology | 2021

von Lotan, I. | Wilf-Yarkoni, A. | Friedman, Y. | +3

4

Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS) : Early experience from a tertiary MS center in Israel

enthalten in: European Journal of Neurology | 2021

von Lotan, I. | Wilf‐Yarkoni, A. | Friedman, Y. | +3

1
[1]